Name: The Future of Oncology: Key Investment Areas and Advancements in Treatment Methodologies
Start: 2025-01-14T15:50:00-0800
End: 2025-01-14T16:30:00-0800

Tuesday January 14, 2025 3:50pm - 4:30pm PST

Hyatt Regency San Francisco

ADCs, bispecifics and radiopharmaceuticals are making waves in oncology treatment. Practice-changing clinical data have spurred major investments and deals. At the same time, much-touted cell therapies have run into real-world issues such as capacity and infrastructure limitations. During this panel, we will explore what’s next for these trends as the industry continues its efforts to advance patient care.

Moderators

Angus Liu

Deputy Editor, Fierce Pharma

Angus is a deputy editor with Fierce Pharma. He earned his Master’s at Northwestern University’s Medill School of Journalism, where he worked as a health reporter besides learning pertinent skills in magazine editing and interactive production. Prior to Medill, he worked as a... Read More →

Speakers

Hesham Abdullah

Senior Vice President, Global Head Oncology, Research & Development, GSK

Hesham Abdullah is a seasoned physician-scientist who uniquely combines a clinician’s understanding of the impact cancer has on patients with deep expertise in identifying transformational opportunities to improve cancer treatment and care.As the head of GSK’s global oncology... Read More →

Teresa Bitetti

President of the Global Oncology Business Unit and a member of the Executive Team, Takeda

Teresa Bitetti is President of the Global Oncology Business Unit and a member of the Executive Team at Takeda, where she oversees a global portfolio of therapies targeting gastrointestinal, thoracic, and hematological cancers. In this role, Teresa leads all aspects of Takeda’s multi-billion-dollar... Read More →

Bassil I. Dahiyat, Ph.D.

President & Chief Executive Officer, Xencor

Bassil Dahiyat has been Xencor’s president and chief executive officer since the Company’s incorporation in August 1997. He is the co-founder of Xencor and co-inventor of Xencor’s breakthrough XmAb® technology. He has led the Company in creating a diverse clinical-stage portfolio... Read More →

Puja Sapra

Senior Vice President, Biologics Engineering & Oncology Targeted Delivery, AstraZeneca

I serve as Vice President, Tumour Targeted Delivery, Early Oncology. In my current role, I lead the research group dedicated to the discovery and preclinical development of targeted cancer therapeutics and novel delivery mechanisms that selectively attack cancer cells while sparing... Read More →

Mai-Britt Zocca, Ph.D.

Founder and Chief Executive Officer, IO Biotech

Dr. Zocca brings more than 20 years of experience in the biotechnology field and has founded and co-founded several biotech spinouts. Her focus on translational and clinical immune oncology has led to the development of important investigational immunotherapies for a variety of cancer... Read More →

Tuesday January 14, 2025 3:50pm - 4:30pm PST
Hyatt Regency San Francisco

Panel

Qtag Featured

Fierce JPM Week 2025